Modern approaches to the treatment of gastric neuroendocrine tumors

Abstract

Gastrointestinal neuroendocrine tumors (GI-NETs) include a wide range of tumors with different variants of the course of the disease. At the one end of the clinical spectrum there are highly differentiated type I GI-NETs, with five-year survival rate over 95%, at the another end there are low-differentiated neuroendocrine carcinoma (large-, smallcell cancers) representing a tumor with extremely poor prognosis. Therapeutic approaches to different types of tumors are different. It is necessary to distinguish the treatment of well-differentiated neuroendocrine neoplasms (I and II clinical-morphological type) and low-differentiated neuroendocrine carcinomas. At the same time, it should be noted how different is the treatment of well-differentiated neuroendocrine tumors with high proliferative activity index (III clinico-morphological type of tumor) and low-differentiated neuroendocrine carcinomas (large-, small-cell cancers).

Keywords

review / NET / carcinoid / neuroendocrine tumor

References

[1] Перфильев И.Б., Кувшинов Ю.П., Унгиадзе Г.В., Малихова О.А., Поддубный Б.К., Делекторская В.В. и др. Междисциплинарный подход в диагностике и лечении нейроэндокринных опухолей желудка. В кн.: Материалы XVII Российско-Японского симпозиума: «Воспоминание о будущем эндоскопии», 19-21 февраля 2015 года, Москва.

[2] Oberg K. Management of neuroendocrine tumours. Ann. Oncol. 2004; 15 (Suppl 4): 293-8.

[3] Delle Fave G., Kwekkeboom D.J., Van Cutsem E., Rindi G. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012; 95: 74-87.

[4] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) NCCN.org

[5] Basuroy R., Srirajaskanthan R., Prachalias A. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment. Pharmacol. Ther. 2014; 39(10): 1071-84.

[6] Borch K., Ahren B., Ahlman H. et al. Gastric carcinoids biologic behavior and prognosis after differentiated treatment in relation to type. Ann. Surg. 2005; 242: 64-73.

[7] Crosby D.A., Donohoe C.L., Fitzgerald L., Muldoon C., Hayes B., O’Toole D., Reynolds J.V. Gastric neuroendocrine tumours. Dig. Surg. 2012; 29: 331-48.

[8] Ahlman H., Kolby L., Lundell L., Olbe L., Wängberg B., Granérus G. et al. Clinical management of gastric carcinoid tumors. Digestion. 1994; 55 (Suppl. 3): 77-85.

[9] Schindl M., Kaserer K., Niederle B. Treatment of gastric neuroendocrine tumors: necessity of a type-adapted treatment. Arch. Surg. 2001; 136: 49-54.

[10] Campana D., Nori F., Pezzilli R., Piscitelli L., Santini D., Brocchi E. et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr. Relat. Cancer. 2008;1 5: 337-42.

[11] Jianu C.S., Fossmark R., Syversen U., Hauso O., Fykse V., Waldum H.L. Five-year follow-up of patients treated for 1 year with octreotide longacting release for enterochromaffin-like cell carcinoids. Scand. J. Gastroenterol. 2011; 46: 456-63.

[12] Merola E., Sbrozzi-Vanni A., Panzuto F. et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012; 95(3): 207-13.

[13] Ramage J.K., Ahmed A., Ardill J., Bax N., Breen D.J., Caplin M.E. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61: 6-32.

[14] Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann. Oncol. 2001; 12 (Suppl 2): S111-14.

[15] Kvols L.K., Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. Am. J. Med. 1987; 82: 77-83.

[16] Christopoulos C., Papavassiliou E. Gastric neuroendocrine tumors: biology and menegement. Ann. Gastroenterol. 2005; 18(2): 127-40.

[17] Oberg K. Management of neuroendocrine tumors: current and future therapies. Expert. Rev. Endocrinol. Metab. 2011; 6(1): 49-62.

[18] Arai K., Matsuda M. Gastric small-cell carcinoma in Japan: a case report and review of the literature. Am. J. Clin. Oncol. 1998; 21(5): 458-61.

[19] Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002; 346: 85-91.

[20] Okita Tsuda N., Kato K., Takahari D., Hirashima Y., Nakajima T.E., Matsubara J. et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011; 14: 161-5.

[21] Nilsson O., van Cutsem E., Delle Fave G., Yao J.C., Pavel M.E., McNicol A.M. et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006; 84(3): 212-5.

[22] Arnold R. Medical treatment of metastasizing carcinoid tumors. World J. Surg. 1996; 20: 203-7.

[23] Kölby L., Bernhardt P., Sward C., Johanson V., Ahlman H., Forssell-Aronsson E. et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Reg. Pept. 1991, 120: 269-73.

[24] Modlin I.M., Moss S.F., Oberg K., Padbury R., Hicks R.J., Gustafsson B.I. et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med. J. Aust. 2010; 193: 46-52.

[25] Rinke A., Müller H.-H., Schade-Brittinger C., Klose K.-J., Barth P., Wied M. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 2009; 27(28): 4656-63.

[26] Jensen R.T., Berna M.J., Bingham D.B., Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008; 113(7, Suppl.): 1807-43.

[27] Castellano D., Bajetta E., Panneerselvam A., Saletan S., Kocha W., O’Dorisio T. et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist. 2013; 18(1): 46-53.

RIGHTS & PERMISSIONS

Eco-Vector